Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website.

Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
Letter to the Editors-in-Chief

Severe arterial thrombosis associated with Covid-19 infection

ARTICLE INFO

Keywords:
Arterial thrombosis
SARS-CoV2 infection
COVID-19
Lower limb ischemia
Floating aortic thrombus

Dear Editor

We were very interested to read the article published by Klok et al. reporting the incidence of thrombotic complications in critically ill ICU patients diagnosed with Covid-19 [1]. The article highlighted the high rate of venous thromboembolism (VTE) and arterial thrombotic events within this population. Many publications have reported cardiovascular complications associated to SARS-CoV2 infection [1–4]. However, few are focused on systemic arterial embolism [1].

We report seven cases of severe arterial thrombotic events in patients infected with Covid-19. These patients developed rapidly progressive lower limb ischemia or formation of mobile aortic thrombi (Table 1). Covid-19 diagnosis was made by PCR assay and/or chest computed tomography (CT) associated to respiratory symptoms in all cases. In case of respiratory deterioration, CT pulmonary angiography was performed to look for an acute pulmonary embolism (PE). Symptomatic arterial thrombosis was diagnosed clinically and confirmed by a color Doppler duplex ultrasonography (CDDUS) and/or CT angiography (CTA).

All patients had a history of cardiovascular disease (Table 1). Five patients were diagnosed with irreversible lower limb ischemia or formation of mobile aortic thrombi. In two cases, therapeutic anticoagulation had to be switched to a prophylactic dose 72 hours before the arterial event because of melena. A conservative treatment was decided by a multidisciplinary team considering the severity of respiratory distress and multiple organ dysfunction. In two cases, asymptomatic floating thoracic aortic thrombi were detected on a pulmonary angiography that had been performed after respiratory deterioration. No previous images were available for comparison.

Two patients had history of lower limb vascular surgery. One of them underwent surgery after lower limb CDDUS confirmed long segment occlusion from the right common iliac artery to the femoral tripod. On day one post revascularization and transfemoral amputation, despite therapeutic anticoagulation, severe left leg ischemia prompted the performance of an abdominal CTA. We diagnosed a suspended thrombus in the deep femoral artery with intra-abdominal floating thrombi. The second patient occluded a previously patent femoral artery bypass in the absence of known triggers.

In addition, among all patients, two of them also presented VTE, one deep vein thrombosis and one segmental PE.

We describe very severe arterial thrombotic complications occurring in COVID-19 patients despite the use of antiplatelet or anticoagulant therapy, including irreversible lower limb ischemia and free floating thrombi in the thoracic aorta. Since the beginning of the pandemic we have noticed an unusual severity of lower limb ischemia, partly explained by the healthcare system saturation resulting in delayed patient presentation. We were also confronted with unusual extension or localization of arterial thrombosis diagnosed in a short period of time.

Other studies have shown cardiovascular disease to be an independent risk factor of pejorative outcome, and myocardial injury to be associated to a heavy mortality rate in COVID-19 [2–4]. Recent publications have highlighted a coagulation disorder in severely diseased patients [3,5], responsible for a hypercoagulable state which might explain disseminated intravascular coagulation and organ failure. Some hypothesize a direct effect of coronavirus on vascular endothelial cells to justify acute arterial thrombosis [4,6]. As a result, systematic thrombosis prophylaxis in patients presenting sepsis induced coagulopathy score ≥4 or D-dimer > 3.0 μg/mL is recommended [6]. Klok et al. brought to light VTE occurring in ICU patients despite this prophylaxis, and suggested a need to increase dosage of anticoagulant treatment for patients with high venous thrombotic risk.

Further studies and publications about SARS-CoV2 infection with a focus on arterial thrombotic complications are needed to characterize arterial consequences of coronavirus and to evaluate the necessity of therapeutic anticoagulation in COVID-19 patients with peripheral arterial occlusive disease or thrombophilia.

Declarations of interest

None

Funding sources

None.
| Case  | Baseline characteristics | Usual antithrombotic treatment | Antithrombotic treatment at time of arterial event | Covid infection | Arterial thrombosis | Days from disease onset to thrombotic event | Symptomatology at the time of diagnosis | Imaging exam | Treatment | VTE associated | D-dimer (µg/L) | Fibrinogen (g/L) | Platelets (/mm³) |
|-------|--------------------------|-------------------------------|-----------------------------------------------|----------------|---------------------|------------------------------------------|-----------------------------------------|-------------|-----------|---------------|----------------|----------------|-----------------|
| 1     | 67, female, Diabetes     | No                            | Aspirin 75 mg/day                             | PCR Not done   | NA                  | 13                         | Bilateral irreversible lower limb ischemia | No          | Medical   | No            | NA             | 12000          | 120000          |
| 2     | 58, female, Hypertension | No                            | Rivaroxaban 20 mg/day                         | Positive       | Descending thoracic aorta | 0                          | Incidental diagnosis                       | CTA         | Medical   | No            | 1200          | 7.1            | 308000         |
| 3     | 69, male, Stroke, Essential thrombocythaemia, Hypertension | Aspirin 75 mg/day and prophylactic anticoagulation | Prophylactic anticoagulation*                 | Positive       | Aortic arch and descending thoracic aorta | 14                         | Incidental diagnosis                       | CTA         | Medical   | No            | > 20000        | > 20000        | 700000         |
| 4     | 71, male, Homozygous factor V Leiden mutation, Hypertension, Deep vein thrombosis (44 PY) | Aspirin 75 mg/day and prophylactic anticoagulation* | Prophylactic anticoagulation*                 | Positive       | Right popliteal artery | 4                          | Irreversible ischemia of the right leg | CDDUS       | Medical   | No            | NA             | NA             | 80000          |
| 5     | 59, male, Hypertension, COPD, active smoking | Rivaroxaban 20 mg/day | Apixaban 10 mg/day | Positive | Left common femoral artery | 0                          | Irreversible ischemia of the left leg | CDDUS       | Medical   | No            | NA             | NA             | 80000          |
| 6     | 82, male, Atrial fibrillation, Chronic renal failure, Hypertension, PAOD, Weaned smoking (50 PY) | Aspirin 75 mg/day, Warfarin | Apixaban 10 mg/day | Positive | Right iliac artery and femoral tripod | 0                          | Irreversible ischemia of the right leg | CDDUS, CTA | Medical   | No            | NA             | 367000         | 173000         |
| 7     | 64, male, Hypertension, PAOD, Weaned smoking (50 PY) | Apixaban 75 mg/day | Aspirin 75 mg/day and prophylactic anticoagulation* | Positive | Right femoro-popliteal bypass | 0                          | Irreversible ischemia of the right leg | CDDUS, CTA | Medical   | No            | 12000         | 12000          | 700000         |

BMI: Body mass index, PY: Pack-years, COPD: Chronic obstructive pulmonary disease, PAOD: Peripheral arterial occlusive disease, *: curative anticoagulation suspended due to melena, PCR: Polymerase chain reaction, CT: Computed tomography, CTA: CT Angiography, CDDUS: Color doppler duplex ultrasonography, VTE: Venous thromboembolism, PE: Pulmonary embolism, NA: Not Applicable.
Acknowledgements

None

References

[1] F.A. Klok, M.J.H.A. Kruij, N.J.M. van der Meer, et al., Incidence of thrombotic complications in critically ill ICU patients with COVID-19, Thromb Res. (2020), https://doi.org/10.1016/j.thromres.2020.04.011.

[2] M. Madjid, P. Safavi-Naeini, S.D. Solomon, O. Vardeny, Potential effects of coronaviruses on the cardiovascular system: a review, JAMA Cardiol. (2020), https://doi.org/10.1001/jamacardio.2020.1286.

[3] E. Driggin, M.V. Madhavan, B. Bikdeli, et al., Cardiovascular considerations for patients, health care workers, and health systems during the coronavirus disease 2019 (COVID-19) pandemic, J Am Coll Cardiol. (2020), https://doi.org/10.1016/j.jacc.2020.03.031.

[4] C.M. Campbell, R. Kahwash, Will complement inhibition be the new target in treating COVID-19 related systemic thrombosis? Circulation. (2020), https://doi.org/10.1161/CIRCULATIONAHA.120.047419.

[5] H. Han, L. Yang, R. Liu, et al., Prominent changes in blood coagulation of patients with SARS-CoV-2 infection, ClinChemLab Med. (2020), https://doi.org/10.1515/cclm-2020-0188.

[6] N. Tang, H. Bai, X. Chen, J. Gong, D. Li, Z. Sun, Anticoagulant treatment is associated with decreased mortality in severe coronavirus disease 2019 patients with coagulopathy, J ThrombThrombolast. (2020), https://doi.org/10.1111/jth.14817.

Mahine Kashia⁎, Aurélien Jacquinb, Bassel Dakhila, Rym Zaimia, Emmanuel Mahéb, Emilie Tellab, Patrick Bagana

a Department of Vascular and Thoracic Surgery, Victor Dupouy Hospital, Argenteuil, France

b Department of Vascular Medicine and Dermatology, Victor Dupouy Hospital, Argenteuil, France

E-mail address: mahine.kashidakhil@ch-argenteuil.fr (M. Kashil).

⁎Corresponding author at: Victor Dupouy Hospital, Department of Vascular and Thoracic Surgery, 69 rue du Lieutenant Colonel Prud'Hon, 95100 Argenteuil, France.